Worldwide Cough Syrup Industry to 2027 - Increasing Number of Patients Suffering from Respiratory Disease is Driving Growth


Dublin, May 21, 2021 (GLOBE NEWSWIRE) -- The "Cough Syrup Market by Product Type, Age Group and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global cough syrup market was valued at $5,232.73 million in 2019, and is projected to reach $6,108.25 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.

Cough is one of the most common symptoms for which patients seek medical attention from primary care physicians and pulmonologists. Cough is an important defensive reflex that enhances the clearance of secretions and particles from the airways and protects the lower airways from foreign materials. Therapeutic suppression of cough may be either disease-specific or symptom related. The potential benefits of an early treatment of cough could include the prevention of the vicious cycle of cough.

The growth of the global cough syrup market is majorly driven by rise in respiratory disorders. In addition, increase in geriatric population and immense air pollution further drive the growth of the market. However, misuse of cough syrup and stringent regulatory framework hinder the market growth. Conversely, high market potential in untapped emerging economies is expected to provide lucrative growth opportunities for the market growth.

The cough syrup market is segmented on the basis of product type, age group, distribution channel, and region. By product, the market is divided into expectorants, cough suppressants/antitussives, and combination medications. On the basis of age group, the cough syrup market is bifurcated into pediatric and adult. By distribution channel, the market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • This report entails a detailed quantitative analysis along with the current global cough syrup market trends from 2020 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The market forecast is studied from 2020 to 2027.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global cough syrup market.

Key Topics Covered:

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
1.4.4. Primary Research

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Player Positioning, 2019
3.3. Porter's Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increasing Number of Patients Suffering from Respiratory Disease
3.4.1.2. Advancements in Cough Syrup Product
3.4.1.3. Rise in Elderly Population
3.4.2. Restraints
3.4.2.1. Cough Syrup Abuse
3.4.2.2. Stringent Rules and Regulation in the Developed Countries
3.4.3. Opportunity
3.4.3.1. Emerging Market
3.5. COVID-19 Impact Analysis for Cough Syrup Market

Chapter 4: Cough Syrup Market, by Product Type

Chapter 5: Cough Syrup Market, by Age Group

Chapter 6: Cough Syrup Market, by Distribution Channel

Chapter 7: Cough Syrup Market, by Region

Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves and Developments
8.2. Acella Pharmaceuticals, LLC
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. GlaxoSmithKline plc
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Johnson & Johnson Services Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Merck KGaA
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves and Developments
8.6. Novartis International Ag
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Pfizer Inc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves and Developments
8.8. Procter & Gamble
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Reckitt Benckiser Group plc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Sanofi
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves and Developments

For more information about this report visit https://www.researchandmarkets.com/r/xcuqso

 

Contact Data